UK renews approval for Zila's oral cancer test "indefinitely"
This article was originally published in Clinica
The UK's Medicine's and Healthcare products Regulatory Agency (MHRA) has renewed the marketing authorisation for Zila's oral cancer diagnostic kit, OraTest. Under the EU's mutual recognition procedure (where approval in one member state is recognised by others), the Phoenix, Arizona firm expects to receive renewal licences in six other member states: Finland, Greece, Luxembourg, the Netherlands and Portugal. OraTest is indicated as an adjunct to visual examination in patients at high risk for oral cancer, or to monitor patients who have previously had the disease. It contains Zila's tolonium chloride rinse product, which is combined with the firm's ViziLite chemiluminescent light source to identify suspicious lesions.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.